Go Pro
→ Stranded On The Flood Plains of History (From Porter & Company) (Ad)tc pixel Free AIDX Stock Alerts

20/20 Biolabs (AIDX) Competitors

20/20 Biolabs logo
$0.62 +0.01 (+1.46%)
Closing price 07/6/2026 04:00 PM Eastern
Extended Trading
$0.60 -0.02 (-3.21%)
As of 07/6/2026 07:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AIDX vs. XBP, GRNQ, QRHC, PMEC, and JOB

Should you buy 20/20 Biolabs stock or one of its competitors? MarketBeat compares 20/20 Biolabs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 20/20 Biolabs include XBP Global (XBP), Greenpro Capital (GRNQ), Quest Resource (QRHC), Primech (PMEC), and GEE Group (JOB). These companies are all part of the "business services" industry.

How does 20/20 Biolabs compare to XBP Global?

XBP Global (NASDAQ:XBP) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

XBP Global has a net margin of 130.26% compared to 20/20 Biolabs' net margin of 0.00%. XBP Global's return on equity of 1,645.47% beat 20/20 Biolabs' return on equity.

Company Net Margins Return on Equity Return on Assets
XBP Global130.26% 1,645.47% 146.77%
20/20 Biolabs N/A N/A N/A

In the previous week, XBP Global's average media sentiment score of 0.00 equaled 20/20 Biolabs'average media sentiment score.

Company Overall Sentiment
XBP Global Neutral
20/20 Biolabs Neutral

XBP Global currently has a consensus price target of $5.00, indicating a potential upside of 104.08%. 20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 701.28%. Given 20/20 Biolabs' higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than XBP Global.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBP Global
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

15.7% of XBP Global shares are owned by institutional investors. 31.4% of XBP Global shares are owned by insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

XBP Global has higher revenue and earnings than 20/20 Biolabs. 20/20 Biolabs is trading at a lower price-to-earnings ratio than XBP Global, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBP Global$791.04M0.04$1.10B-$3.28N/A
20/20 Biolabs$1.84M4.14-$3.43M-$0.28N/A

Summary

XBP Global beats 20/20 Biolabs on 7 of the 10 factors compared between the two stocks.

How does 20/20 Biolabs compare to Greenpro Capital?

20/20 Biolabs (NASDAQ:AIDX) and Greenpro Capital (NASDAQ:GRNQ) are both small-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Greenpro Capital has higher revenue and earnings than 20/20 Biolabs. Greenpro Capital is trading at a lower price-to-earnings ratio than 20/20 Biolabs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$1.84M4.14-$3.43M-$0.28N/A
Greenpro Capital$2.07M12.46-$2.98M-$0.39N/A

0.9% of Greenpro Capital shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by company insiders. Comparatively, 39.7% of Greenpro Capital shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

20/20 Biolabs has a net margin of 0.00% compared to Greenpro Capital's net margin of -153.32%. 20/20 Biolabs' return on equity of 0.00% beat Greenpro Capital's return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
Greenpro Capital -153.32%-31.13%-25.47%

20/20 Biolabs currently has a consensus price target of $5.00, suggesting a potential upside of 701.28%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, equities analysts clearly believe 20/20 Biolabs is more favorable than Greenpro Capital.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Greenpro Capital
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Greenpro Capital had 4 more articles in the media than 20/20 Biolabs. MarketBeat recorded 4 mentions for Greenpro Capital and 0 mentions for 20/20 Biolabs. Greenpro Capital's average media sentiment score of 1.30 beat 20/20 Biolabs' score of 0.00 indicating that Greenpro Capital is being referred to more favorably in the news media.

Company Overall Sentiment
20/20 Biolabs Neutral
Greenpro Capital Positive

Summary

20/20 Biolabs beats Greenpro Capital on 8 of the 15 factors compared between the two stocks.

How does 20/20 Biolabs compare to Quest Resource?

20/20 Biolabs (NASDAQ:AIDX) and Quest Resource (NASDAQ:QRHC) are both small-cap business services companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

20/20 Biolabs has a net margin of 0.00% compared to Quest Resource's net margin of -3.00%. 20/20 Biolabs' return on equity of 0.00% beat Quest Resource's return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
Quest Resource -3.00%-12.30%-3.39%

In the previous week, 20/20 Biolabs' average media sentiment score of 0.00 equaled Quest Resource'saverage media sentiment score.

Company Overall Sentiment
20/20 Biolabs Neutral
Quest Resource Neutral

20/20 Biolabs has higher earnings, but lower revenue than Quest Resource. Quest Resource is trading at a lower price-to-earnings ratio than 20/20 Biolabs, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$1.84M4.14-$3.43M-$0.28N/A
Quest Resource$250.22M0.11-$15.38M-$0.34N/A

48.2% of Quest Resource shares are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by insiders. Comparatively, 19.6% of Quest Resource shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

20/20 Biolabs presently has a consensus target price of $5.00, indicating a potential upside of 701.28%. Quest Resource has a consensus target price of $2.25, indicating a potential upside of 80.00%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than Quest Resource.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Quest Resource
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33

Summary

20/20 Biolabs beats Quest Resource on 11 of the 13 factors compared between the two stocks.

How does 20/20 Biolabs compare to Primech?

Primech (NASDAQ:PMEC) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

88.1% of Primech shares are owned by institutional investors. 29.8% of 20/20 Biolabs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Primech has higher revenue and earnings than 20/20 Biolabs.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Primech$74.35M0.33-$1.94MN/AN/A
20/20 Biolabs$1.84M4.14-$3.43M-$0.28N/A

Company Net Margins Return on Equity Return on Assets
PrimechN/A N/A N/A
20/20 Biolabs N/A N/A N/A

In the previous week, Primech's average media sentiment score of 0.00 equaled 20/20 Biolabs'average media sentiment score.

Company Overall Sentiment
Primech Neutral
20/20 Biolabs Neutral

20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 701.28%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than Primech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Primech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

20/20 Biolabs beats Primech on 5 of the 8 factors compared between the two stocks.

How does 20/20 Biolabs compare to GEE Group?

GEE Group (NYSE:JOB) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

20/20 Biolabs has a net margin of 0.00% compared to GEE Group's net margin of -20.77%. 20/20 Biolabs' return on equity of 0.00% beat GEE Group's return on equity.

Company Net Margins Return on Equity Return on Assets
GEE Group-20.77% -7.66% -6.84%
20/20 Biolabs N/A N/A N/A

In the previous week, GEE Group's average media sentiment score of 0.00 equaled 20/20 Biolabs'average media sentiment score.

Company Overall Sentiment
GEE Group Neutral
20/20 Biolabs Neutral

20/20 Biolabs has lower revenue, but higher earnings than GEE Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GEE Group$87.98M0.27-$24.10MN/AN/A
20/20 Biolabs$1.84M4.14-$3.43M-$0.28N/A

20/20 Biolabs has a consensus target price of $5.00, indicating a potential upside of 701.28%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than GEE Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GEE Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

30.4% of GEE Group shares are owned by institutional investors. 17.0% of GEE Group shares are owned by company insiders. Comparatively, 29.8% of 20/20 Biolabs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

20/20 Biolabs beats GEE Group on 9 of the 12 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Sign up to receive the latest news and ratings for AIDX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AIDX vs. The Competition

Export
Metric20/20 BiolabsServices – Research, Development, Testing Labs IndustryServices SectorNASDAQ Exchange
Market Cap$7.65M$9.10M$24.62B$12.59B
Dividend YieldN/AN/A5.23%6.52%
P/E Ratio-2.23N/A18.7124.81
Price / Sales4.142.6840.6089.92
Price / CashN/AN/A57.8649.23
Price / BookN/A0.2412.686.50
Net Income-$3.43M-$15.16M-$14.47M$336.03M
7 Day Performance13.52%2.51%-0.49%2.68%
1 Month Performance-22.19%-18.55%6.32%5.50%
1 Year PerformanceN/AN/A-8.20%25.01%

20/20 Biolabs Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AIDX
20/20 Biolabs
1.6195 of 5 stars		$0.62
+1.5%		$5.00
+701.3%		N/A$7.65M$1.84MN/A14
XBP
XBP Global
3.6644 of 5 stars		$2.46
-2.8%		$5.00
+103.4%		-73.7%$28.93M$791.04MN/A10,600
GRNQ
Greenpro Capital
1.3502 of 5 stars		$1.54
-1.3%		N/A-13.4%$27.77M$2.07MN/A60
QRHC
Quest Resource
3.2273 of 5 stars		$1.24
-0.4%		$2.25
+82.2%		-43.7%$26.03M$243.52MN/A190
PMEC
Primech
0.5842 of 5 stars		$0.65
-3.5%		N/A-56.4%$24.82M$74.35MN/A2,806

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 7/7/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel